CFH and Dravet syndrome: One of the targets of miR-155 is complement factor H mRNA (CFH), a soluble innate-immune regulatory glycoprotein in AD and DS tissues and in primary brain experimental models of AD, which are also centrally involved in pathogenic signaling pathways that include inflammatory neurodegeneration [126].